Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)

Next Previous
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Acute asthma; Asthma; Eosinophilia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMET
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

    • Most Recent Events

    • 25 Jun 2021 Results assessing clinical impact of stopping mepolizumab 100 mg SC in patients with severe eosinophilic asthma following long-term (greater than equal to 3 years) exposure by assessing exacerbation rates and other clinical parameters in those who stopped mepolizumab (and switched to placebo) versus those who continued, published in the European Respiratory Journal.
    • 19 May 2021 Results of a secondary analysis assessing whether patient baseline characteristics can predict the outcome of stopping versus continuing long-term mepolizumab treatment in patients with severe eosinophilic asthma presented at the 117th International Conference of the American Thoracic Society
    • 20 May 2020 Primary endpoint has been met. (time to first clinically significant exacerbation) as per Results presented at the 116th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top